All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » Could crowdfunding be the savior of early-stage med-tech?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Could crowdfunding be the savior of early-stage med-tech?

Oct. 25, 2013
By Omar Ford
No Comments

crowd-fundingIt's no secret that it's harder and harder for med-tech firms to receive early stage funding. I think my last six blogs have been about that topic alone.

But while its true that some venture capital firms are looking to invest in med-tech companies at a later stage in the development cycle, some firms are getting fairly creative and are going toward crowdfunding.

Last  week, I wrote a story about Amulyte (Markham, Ontario), a company that has developed an emergency response device that helps seniors live on their own terms, and its move toward the crowdfunding model. The company partnered with WeFunder, a recently launched Crowd Investing platform that helps early stage companies secure investment.

It was an interesting interview and Mike Norman co-founder and president of WeFunder spoke on some ambivalence that some companies might have toward going this route.

“Any time there’s a new innovation out there with something as critical as fundraising . . . people really want to understand how it works,” he said in an interview with Medical Device Daily. “We have had to make our model look as similar to existing fundraising as possible. One of the things that start-ups get concerned about is having hundreds of investors in the company with voting rights and they have to get signatures from these investors, which are just hard to track down in general, when they want to make large company decisions. What we do is we take all the investors that come in through the WeFunder and they invest in a single LLC that then invests in the company.”

He then said that because of this measure there is only one shareholder on the company’s cap table.

With this kind of model in place I have to wonder if med-tech firms truly want to keep up with the times and foster innovation, could they quite possibly think about crowdfunding as a means of early-stage funding?

We're in an era where med-tech companies that think outside the box could lead the pack in innovation. Could crowdfunding be the next logical step in achieving this goal?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing